8-K: Veru Inc. Reports Q3 FY26 Results, Advances Obesity Drug Trial

Veru Inc. announced fiscal 2026 third quarter financial results, highlighting full enrollment in its Phase 2b PLATEAU clinical trial for enobosarm and semaglutide combination therapy for weight loss, alongside a significant patent allowance.

Summary

• Veru Inc. reported financial results for the third quarter and nine months ended June 30, 2026.
• The Phase 2b PLATEAU clinical trial for enobosarm and semaglutide in older patients with obesity is fully enrolled with 239 patients.
• An interim analysis of the Phase 2b PLATEAU trial is expected in Q1 2027, with final topline data anticipated in Q4 2027.
• The company received a Notice of Allowance from the USPTO for a key U.S. patent for enobosarm and semaglutide, expected to provide protection until at least October 2044.
• Research and development expenses for the nine months ended June 30, 2026, were $8.8 million, a decrease from $12.7 million in the prior year.
• General and administrative expenses for the nine months decreased to $11.5 million from $15.4 million.
• The net loss for the nine months was $15.1 million, or $0.68 per share, an improvement from a net loss of $24.2 million, or $1.65 per share, in the prior year.
• Cash, cash equivalents, and restricted cash stood at $23.9 million as of June 30, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, driven by clinical trial progress and patent allowance, despite ongoing operational losses.

Positives

• Full enrollment achieved in the Phase 2b PLATEAU clinical trial with 239 patients, exceeding the target of 200.
• USPTO Notice of Allowance received for a key U.S. patent for enobosarm and semaglutide combination, expected to provide patent protection until at least October 2044.
• Significant reduction in net loss for the nine months ended June 30, 2026 ($15.1 million) compared to the same period in the prior year ($24.2 million).
• Reduction in both research and development and general and administrative expenses year-to-date.
• Increased cash, cash equivalents, and restricted cash to $23.9 million as of June 30, 2026, from $15.8 million as of September 30, 2025.
• Positive results from the completed Phase 2b QUALITY clinical study, showing enobosarm plus semaglutide preserved lean mass and physical function, and led to greater fat loss.

Negatives

• Operating loss from continuing operations increased to $7.7 million for the three months ended June 30, 2026, from $7.5 million in the prior year.
• Net loss for the three months ended June 30, 2026, was $7.0 million, or $0.30 per share, compared to $7.3 million, or $0.50 per share, in the prior year, indicating continued operational losses.
• The company's advancement of its sabizabulin program is dependent on securing additional funding.

Risks

• Potential delays in the timing of and results from clinical trials, including the inability to enroll sufficient patients or meet planned schedules.
• The FDA may disagree with study design requirements for planned clinical studies, including for enobosarm as a weight loss drug.
• The company may not be able to secure sufficient financing, including partnership or collaboration agreements, to fund development and operations, raising concerns about its ability to continue as a going concern.
• The supply agreement with Novo Nordisk could be terminated by Novo Nordisk with 60 days' prior notice.
• Competition from existing or new competitors with greater resources and capabilities.
• Changes in regulatory practices, policies, or government-driven healthcare reform efforts, including pricing pressures and reimbursement changes.
• Potential disruptions at the FDA or other government agencies could negatively affect the business.

Future Outlook

The company expects to report interim analysis results from the Phase 2b PLATEAU clinical trial in the first quarter of calendar year 2027 and final topline clinical data in the fourth quarter of calendar year 2027. The issuance of a U.S. patent for enobosarm and semaglutide is expected to provide protection until at least October 2044, with a potential formulation patent extending to May 2046. Advancement of the sabizabulin program is contingent on securing additional funding.

Management Comments

• "We are extremely pleased with the continued enobosarm progress during this past quarter. We reached full enrollment of the Phase 2b PLATEAU clinical trial and entered into a clinical supply agreement with Novo Nordisk for the Phase 2b PLATEAU clinical trial."
• "In addition, we received from the USPTO a notice of allowance for a key U.S. patent for enobosarm with semaglutide for high quality weight loss which when issued, will provide U.S. patent protection until at least October 2044."
• "We believe these accomplishments mark important milestones in advancing enobosarm as a potential important combination therapy with GLP-1 receptor agonists."
• "There is a significant unmet medical need to make weight reduction more tissue selective by maximizing fat loss while preserving lean mass, physical function, and bone mineral density for the highest quality weight reduction especially in older patients who have low muscle reserves and obesity."
• "I want to thank both the patients and the investigators for their enthusiasm to expeditiously reach full enrollment for this very important study."
• "We remain on track to achieve the near-term milestone of reporting the interim analysis results from the Phase 2b PLATEAU clinical trial in the first quarter of calendar year 2027."

Industry Context

StockSavvy.ai notes that Veru Inc.'s focus on developing enobosarm in combination with GLP-1 receptor agonists for higher quality weight loss aligns with a significant unmet need in the obesity market, particularly for older patients. The increasing prevalence of obesity and the demand for more effective and tissue-selective weight management solutions position this research within a rapidly growing and competitive therapeutic area.

Comparison to Industry Standards

• The Phase 2b QUALITY study results, showing enobosarm plus semaglutide preserved lean mass and physical function and led to greater fat loss, are positive indicators for the potential of this combination therapy.
• The enrollment of 239 patients in the Phase 2b PLATEAU trial exceeds the targeted 200, suggesting strong interest and feasibility in recruiting for this patient population.
• The USPTO Notice of Allowance for a patent extending to at least October 2044 is a significant positive, providing substantial intellectual property protection in a competitive landscape.
• The company's cash position of $23.9 million provides runway for ongoing clinical development, though further funding will be critical for later-stage trials and commercialization.

Stakeholder Impact

• Shareholders: Potential for increased value if clinical trials are successful and patents are upheld, but ongoing losses and funding needs present risks.
• Patients: Potential for improved treatment options for obesity, particularly for older adults, with a focus on quality weight loss.
• Healthcare Providers: May see new therapeutic options for managing obesity in conjunction with GLP-1 RA treatments.

Next Steps

• Report interim analysis results from the Phase 2b PLATEAU clinical trial in Q1 2027.
• Report final topline clinical data from the Phase 2b PLATEAU clinical trial in Q4 2027.
• Secure additional funding for the advancement of the sabizabulin program.
• Continue to prosecute pending patent applications worldwide.

Key Dates

Recommendation

The company shows promising clinical trial progress and strong intellectual property development in a high-demand area (obesity). However, continued operational losses, dependence on future funding, and the inherent risks of clinical development warrant a cautious 'hold' stance until further data and financial stability are demonstrated.

Keywords

enobosarm, semaglutide, obesity, weight loss, clinical trial, biopharmaceutical, cardiometabolic, patent